Shilpa Medicare Peer Comparison
NSE: SHILPAMED | BSE: 530549
₹922.10
As on 15-Oct-2026IST
Market cap
₹18,056 Cr
Revenue (TTM)
₹1,682 Cr
P/E Ratio
60.7
P/B Ratio
6.7
Div. Yield
0.1 %
| Shilpa Medicare | Astrazeneca Pharma | Bliss GVS Pharma | Caplin Point Lab | CORONA Remedies | Eris Lifesciences | Pfizer | Procter & Gamble Health | Strides Pharma | Supriya Lifescience | |
|---|---|---|---|---|---|---|---|---|---|---|
Market cap (₹ Cr) |
18,056 | 14,807 | 6,940 | 17,505 | 12,478 | 15,872 | 17,424 | 8,526 | 9,789 | 7,025 |
Revenue (₹ Cr) |
1,682 | 2,432 | 1,005 | 2,287 | 1,479 | 3,230 | 2,570 | 1,433 | 5,004 | 873 |
Net Profit (₹ Cr) |
273.51 | 169.62 | 141.74 | 678.07 | 198.55 | 666.92 | 735.15 | 356.88 | 635.34 | 198.37 |
Net Margin (%) |
16.19 | 6.90 | 13.31 | 28.10 | 13.32 | 20.60 | 26.88 | 24.61 | 12.33 | 22.44 |
RoE (%) |
11.15 | 20.76 | 11.84 | 19.73 | 30.33 | 18.75 | 19.16 | 58.24 | 19.77 | 17.43 |
Price to Earnings |
60.73 | 87.29 | 50.96 | 26.31 | 62.69 | 24.65 | 23.70 | 23.89 | 15.96 | 35.41 |
Price-To-Book |
6.72 | 16.38 | 5.63 | 4.77 | 15.46 | 3.94 | 3.95 | 13.85 | 2.99 | 5.75 |
Income Statement (₹ Cr)
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,682.47 | 2,287.33 | 2,569.77 | 3,229.67 | 2,432.06 |
|
Total Income
|
1,689.83 | 2,413.29 | 2,735.39 | 3,237.12 | 2,458.54 |
|
Total Expenditure
|
1,203.91 | 1,490.75 | 1,628.14 | 2,090.06 | 2,202.20 |
|
EBITDA
|
478.55 | 796.58 | 941.63 | 1,139.61 | 229.86 |
|
Depreciation
|
126.01 | 78.10 | 57.58 | 281.06 | 17.24 |
|
EBIT
|
352.55 | 718.48 | 884.05 | 858.55 | 212.62 |
|
Interest
|
52.11 | 0.88 | 7.69 | 190.64 | 5.72 |
|
Other Income
|
7.37 | 125.96 | 165.62 | 7.45 | 26.48 |
|
Exceptional Items
|
12.16 | 0.00 | -49.16 | -17.24 | -5.13 |
|
Profit before Tax
|
319.96 | 843.56 | 992.82 | 658.12 | 228.25 |
|
Provision for Tax
|
46.45 | 165.49 | 257.67 | -8.80 | 58.63 |
|
Profit after Tax
|
273.51 | 678.07 | 735.15 | 666.92 | 169.62 |
Liabilities (₹ Cr)
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,591.20 | 3,586.42 | 4,202.90 | 3,902.67 | 872.79 |
|
Minority Interest
|
0.00 | -12.71 | 0.00 | -21.81 | 0.00 |
|
Non-Current Liabilities
|
266.35 | 28.74 | 91.50 | 1,392.75 | 134.50 |
|
Current Liabilities
|
848.06 | 385.94 | 627.48 | 2,077.10 | 981.81 |
|
Total Liabilities
|
3,705.61 | 4,037.51 | 4,921.88 | 7,246.72 | 2,414.58 |
Assets (₹ Cr)
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,525.44 | 1,291.22 | 770.28 | 5,617.77 | 42.47 |
|
Current Assets
|
1,109.77 | 2,585.66 | 3,803.22 | 1,539.85 | 1,739.93 |
|
Total Assets
|
3,705.61 | 4,037.51 | 4,921.88 | 7,246.72 | 2,414.58 |
|
Total Debt*
|
657.97 | 0.57 | 2.50 | 2,309.68 | 0.00 |
|
Net Current Assets
|
261.71 | 2,199.72 | 3,175.74 | -537.25 | 758.12 |
|
Contingent Liabilities
|
160.01 | 17.53 | 370.49 | 51.57 | 121.23 |
Cashflow (₹ Cr)
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
342.18 | 523.24 | 967.57 | 537.99 | -15.14 |
|
Cash Flow from Investing Activities
|
-325.92 | -582.30 | -561.67 | -369.46 | 18.69 |
|
Cash from Financing Activities
|
13.62 | -46.46 | -798.31 | -313.53 | -91.97 |
|
Net Cash Inflow / Outflow
|
29.88 | -105.52 | -392.41 | -145.00 | -88.42 |
Ratios
Profitability Ratios
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.43 | 24.97 | 23.39 | 14.47 | 31.24 |
|
ROE (%)
|
11.15 | 19.73 | 19.16 | 18.75 | 20.76 |
|
ROA (%)
|
7.80 | 18.69 | 14.95 | 9.26 | 9.67 |
|
EBIT Margin (%)
|
20.95 | 31.41 | 34.40 | 26.58 | 8.74 |
|
Net Margin (%)
|
16.19 | 28.10 | 26.88 | 20.60 | 6.90 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
27.91 | 15.01 | 10.69 | 9.59 | 31.10 |
|
EBIT Growth (%)
|
58.32 | 18.45 | 24.14 | 16.84 | -12.99 |
|
Net Profit Growth (%)
|
149.56 | 19.61 | -9.09 | 62.68 | -7.49 |
|
EPS Growth (%)
|
-3.57 | 17.73 | 14.40 | 67.41 | -18.33 |
|
Book Value Growth (%)
|
9.67 | 26.75 | -0.34 | 36.71 | 13.51 |
Valuation Ratios
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
64.55 | 26.22 | 22.64 | 24.18 | 85.99 |
|
Price / Book Value
|
6.74 | 4.75 | 3.96 | 3.96 | 16.50 |
|
Dividend Yield (%)
|
0.06 | 0.35 | 1.97 | 0.00 | 0.60 |
|
EV/EBITDA
|
39.09 | 20.64 | 15.25 | 15.99 | 62.97 |
|
Market Cap (₹ Cr)
|
6,819.66 | 11,439.22 | 21,592.90 | 17,980.08 | 19,398.64 |
Solvency Ratios
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.07 | 0.00 | 0.00 | 0.24 | 0.00 |
|
Short term debt to equity ratio
|
0.16 | 0.00 | 0.00 | 0.12 | -- |
|
Current Ratio
|
1.31 | 6.70 | 6.06 | 0.74 | 1.77 |
|
Quick Ratio
|
0.88 | 5.59 | 5.31 | 0.53 | 0.73 |
|
Interest Coverage
|
7.14 | 959.59 | 130.11 | 4.45 | 40.90 |
Operating Efficiency Ratios
| Shilpa Medicare | Caplin Point Lab | Pfizer | Eris Lifesciences | Astrazeneca Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
30.84 | 36.10 | 7.07 | 21.07 | 8.79 |
|
Asset Turnover
|
0.48 | 0.63 | 0.52 | 0.45 | 1.39 |
|
Receivable days
|
113.81 | 121.68 | 26.06 | 63.88 | 31.88 |
|
Inventory Days
|
84.76 | 63.83 | 65.95 | 43.27 | 126.03 |
|
Payable days
|
101.94 | 108.28 | 81.01 | 151.85 | 163.79 |
|
Cash Conversion Cycle
|
96.62 | 77.23 | 11.00 | -44.70 | -5.88 |